PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32102484-6	2020	Additional targeting of the RAS/RAF/MEK/MAPK pathway with the allosteric MEK1/2 inhibitor AZD6244 showed synergistic effects on the viability of MPNST cell lines in vitro in comparison to the dual AKT/mTOR inhibition.	AZD 6244	90-97	mitogen-activated protein kinase kinase 1	Mus musculus	73-79	
32358092-5	2020	Mice were treated with interferon gamma (IFNgamma) intraperitoneally for 3 days or with the mitogen-activated protein kinase kinase (MEK1/2) inhibitor selumetinib by oral gavage for 24 hours.	AZD 6244	151-162	mitogen-activated protein kinase kinase 1	Mus musculus	133-139	
25326806-2	2015	AZD6244 is a potent, selective, and orally available MEK1/2 inhibitor.	AZD 6244	0-7	mitogen-activated protein kinase kinase 1	Mus musculus	53-59	
31786775-3	2020	In the present study, the effect of AZD6244 (an ATP non-competitive MEK1/2 inhibitor) on acrolein-induced neuroinflammation was investigated using BV-2 cells and primary cultured microglia.	AZD 6244	36-43	mitogen-activated protein kinase kinase 1	Mus musculus	68-74	
25541062-3	2015	Using KRAS-mutant NSCLC cells and a mouse model, we evaluated the efficacy of adding the MEK1/2 inhibitor AZD6244 as an addition for cisplatin-based chemotherapy.	AZD 6244	106-113	mitogen-activated protein kinase kinase 1	Mus musculus	89-95	
22144664-0	2012	MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.	AZD 6244	17-28	mitogen-activated protein kinase kinase 1	Mus musculus	0-6	
24132923-0	2013	Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.	AZD 6244	89-100	mitogen-activated protein kinase kinase 1	Mus musculus	74-78	
24132923-0	2013	Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.	AZD 6244	102-109	mitogen-activated protein kinase kinase 1	Mus musculus	74-78	
24448821-7	2014	We found that the acquired MEK1-C121S mutation in BRAF-V600E mutant melanoma conferred resistance to both vemurafenib and selumetinib but not E6201.	AZD 6244	122-133	mitogen-activated protein kinase kinase 1	Mus musculus	27-31	
23508762-4	2013	Therefore, in the current study, we investigated the effect of inhibiting the growth factor receptor pathways with a MEK-1/2 inhibitor selumetinib (AZD6244, ARRY-142866).	AZD 6244	135-146	mitogen-activated protein kinase kinase 1	Mus musculus	117-124	
22144664-0	2012	MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.	AZD 6244	30-37	mitogen-activated protein kinase kinase 1	Mus musculus	0-6	
17237274-3	2007	In the present study, we determined the efficacy of a specific MEK1/2 inhibitor AZD6244 (ARRAY-142886) in treatment of HCC.	AZD 6244	80-87	mitogen-activated protein kinase kinase 1	Mus musculus	63-69	
20407895-1	2011	PURPOSE: AZD6244 (ARRY-142886) (AstraZeneca, Macclesfield, UK) is a novel small molecule MEK1/2 inhibitor that is currently being tested in Phase II trials.	AZD 6244	9-16	mitogen-activated protein kinase kinase 1	Mus musculus	89-95	
35287697-12	2022	The Homer1 protein and selumetinib, a non-ATP competitive MEK1/2 inhibitor, improved the outcome in ICH in Homer1flox/flox/Nestin-Cre+/- mice.	AZD 6244	23-34	mitogen-activated protein kinase kinase 1	Mus musculus	58-64	
34247190-6	2021	Targeting MEK1 by RNAi or clinically applicable MEK1 inhibitors AZD6244 and GSK1120212 reduces MACC1 tyrosine phosphorylation and restricts MACC1-induced metastasis formation in mice.	AZD 6244	64-71	mitogen-activated protein kinase kinase 1	Mus musculus	10-14	
34247190-6	2021	Targeting MEK1 by RNAi or clinically applicable MEK1 inhibitors AZD6244 and GSK1120212 reduces MACC1 tyrosine phosphorylation and restricts MACC1-induced metastasis formation in mice.	AZD 6244	64-71	mitogen-activated protein kinase kinase 1	Mus musculus	48-52